Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioPlus Acquisition Corp.BIOS · Entity 112459 | Director | December 02, 2021 | December 03, 2021 |
| Cyclo Therapeutics, Inc.CYTH · Entity 82635 | Director | February 27, 2025 | March 03, 2025 |
| GT Biopharma, Inc.GTBP · Entity 7878 | Director · Chief Executive Officer | November 16, 2017 | March 16, 2018 |
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Chief Financial Officer | April 23, 2026 | April 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioPlus Acquisition Corp.
Report date December 02, 2021 · Filed December 03, 2021
This filing explicitly reported no securities owned.
Cyclo Therapeutics, Inc.
Report date February 27, 2025 · Filed March 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 136,346 |
Reported balance
After 2025-02-27 transaction · row 1
1 source rowRow 1 · 2025-02-27 · Grant · Acquired 28,597 · Balance 136,346 F1: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the issuer's non-employee director compensation policy. Grant reflects director compensation for the fourth quarter of 2024 and from January 1, 2025 through March 25, 2025. The number of shares received in lieu of cash was calculated based on the closing price of $0.77 per share of common stock on February 26, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the issuer's non-employee director compensation policy. Grant reflects director compensation for the fourth quarter of 2024 and from January 1, 2025 through March 25, 2025. The number of shares received in lieu of cash was calculated based on the closing price of $0.77 per share of common stock on February 26, 2025.
GT Biopharma, Inc.
Report date November 16, 2017 · Filed March 16, 2018
This filing explicitly reported no securities owned.
Pacira BioSciences, Inc.
Report date April 23, 2026 · Filed April 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 105,341 |
Ending reported balance
After 2026-04-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-23 · Exercise / conversion · Acquired 12,941 · Balance 118,282 F1: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. Row 2 · 2026-04-23 · Sale · Disposed 12,941 · Balance 105,341 F1: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.41, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.45 · Expires 2034-11-04 | Direct | 150,000 |
Reported balance
After 2026-04-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-23 · Exercise / conversion · Disposed 12,941 · Balance 150,000 F1: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. F3: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.41, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Applied Molecular Transport Inc.
Report date December 27, 2023 · Filed December 28, 2023
Section 16 reporting ended · disclosed 2023-12-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-12-27 transaction · row 1
1 source rowRow 1 · 2023-12-27 · Disposition to issuer · Disposed 545,499 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated as of September 21, 2023 (the "Merger Agreement"), by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc. and the Issuer, each share of Issuer's Common Stock was converted into 0.1331 of a share of Cyclo Common Stock (the "Transaction Consideration"). F2: Upon consummation of the Merger, the Reporting Person received Transaction Consideration of 72,606 shares of Cyclo common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.61 · Expires 2030-03-30 | Direct | 0 |
Reported balance
After 2023-12-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-12-27 · Disposition to issuer · Disposed 300,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.61 · Expires 2031-03-01 | Direct | 0 |
Reported balance
After 2023-12-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-12-27 · Disposition to issuer · Disposed 63,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.29 · Expires 2032-02-15 | Direct | 0 |
Reported balance
After 2023-12-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-12-27 · Disposition to issuer · Disposed 94,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.99 · Expires 2032-05-16 | Direct | 0 |
Reported balance
After 2023-12-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-12-27 · Disposition to issuer · Disposed 84,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.39 · Expires 2033-03-24 | Direct | 0 |
Reported balance
After 2023-12-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-12-27 · Disposition to issuer · Disposed 668,000 · Balance 0 F4: Pursuant to the Merger Agreement, this option was exchanged for an option covering 88,910 shares of Cyclo Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger dated as of September 21, 2023 (the "Merger Agreement"), by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc. and the Issuer, each share of Issuer's Common Stock was converted into 0.1331 of a share of Cyclo Common Stock (the "Transaction Consideration").
F2: Upon consummation of the Merger, the Reporting Person received Transaction Consideration of 72,606 shares of Cyclo common stock.
F3: Pursuant to the Merger Agreement, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing.
F4: Pursuant to the Merger Agreement, this option was exchanged for an option covering 88,910 shares of Cyclo Common Stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2022 Filed Jun 3, 2022 19:20 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | SaleCommon Stock | 1,767 | $2.97 | $5,244.28 |
DisclosureSEC source: 0001209191-22-034352 · doc4.xml · nonDerivative · entry 1 Cross Shawn · CIK 0001734779 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,983 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in column is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.81 to $3.33, inclusive. The reporting person undertakes to provide Applied Molecular Transport, Inc., any security holder of Applied Molecular Transport, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: A portion of these securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 16, 2022 Filed May 18, 2022 18:07 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | GrantStock Option (Right to Buy) · Derivative | 84,000 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001209191-22-030208 · doc4.xml · derivative · entry 2 Cross Shawn · CIK 0001734779 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,000 Underlying: Common Stock · 84,000 shares Expires 2032-05-16 F3 · derivative.exercise_date: 1/48th of the shares subject to the option shall become vested and exercisable on the Exercisable Date set forth above and 1/48th of the shares subject to the option shall continue to vest each month thereafter, provided that Reporting Person is a service provider to the Issuer as of each such vesting date. Read SEC document |
| May 16, 2022 Filed May 18, 2022 18:07 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | GrantCommon Stock | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-030208 · doc4.xml · nonDerivative · entry 1 Cross Shawn · CIK 0001734779 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,750 F1 · shares: These securities are Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one shares of the Issuer's Common Stock. 1/16th of the RSUs shall vest on September 1, 2022 and 1/16th of the RSUs shall vest quarterly thereafter, subject to the Reporting Person continuing as a service provider through each such date. F2 · balance_after: A portion of these securities are RSUs. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 19:57 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | GrantStock Option (Right to Buy) · Derivative | 94,500 | $0.00 Strike: $8.29 | $0.00 |
DisclosureSEC source: 0001209191-22-010366 · doc4.xml · derivative · entry 2 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,500 Underlying: Common Stock · 94,500 shares Expires 2032-02-15 F2 · derivative.exercise_date: 1/48th of the shares subject to the option shall become vested and exercisable on the Exercisable Date set forth above and 1/48th of the shares subject to the option shall continue to vest each month thereafter, provided that Reporting Person is a service provider to the Issuer as of each such vesting date. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 19:57 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | GrantCommon Stock | 20,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010366 · doc4.xml · nonDerivative · entry 1 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,750 F1 · shares: These securities are Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one shares of the Issuer's Common Stock. 5/48ths of the RSUs shall vest on June 1, 2022 and 1/16th of the RSUs shall vest quarterly thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| December 24, 2021 Filed Jan 6, 2022 19:22 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | GrantCommon Stock | 31,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002244 · doc4.xml · nonDerivative · entry 1 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 F1 · shares: These securities are Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one shares of the Issuer's Common Stock. 1/4th of the RSUs shall vest on June 1, 2022 and 1/4th of the RSUs shall vest every six months thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| August 23, 2021 Filed Aug 23, 2021 19:40 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,700 | $0.00 Strike: $4.61 | $0.00 |
DisclosureSEC source: 0001209191-21-053042 · doc4.xml · derivative · entry 6 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 9,700 shares Expires 2030-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the shares subject to the option became vested on the Exercisable Date and 1/48th of the shares subject to the option vest monthly thereafter, provided that the reporting person is a service provider to the issuer on each such vest date. Read SEC document |
| August 23, 2021 Filed Aug 23, 2021 19:40 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | SaleCommon Stock | 9,700 | $30.12 | $292,190.19 |
DisclosureSEC source: 0001209191-21-053042 · doc4.xml · nonDerivative · entry 4 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on April 9, 2021. F2 · price: The price reported in column is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.97, inclusive. The reporting person undertakes to provide Applied Molecular Transport, Inc., any security holder of Applied Molecular Transport, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 23, 2021 Filed Aug 23, 2021 19:40 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | Exercise / conversionCommon Stock | 9,700 | $4.61 | $44,717.00 |
DisclosureSEC source: 0001209191-21-053042 · doc4.xml · nonDerivative · entry 3 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 19:40 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | Exercise / conversionStock Option (Right to Buy) · Derivative | 300 | $0.00 Strike: $4.61 | $0.00 |
DisclosureSEC source: 0001209191-21-053042 · doc4.xml · derivative · entry 5 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,700 Underlying: Common Stock · 300 shares Expires 2030-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the shares subject to the option became vested on the Exercisable Date and 1/48th of the shares subject to the option vest monthly thereafter, provided that the reporting person is a service provider to the issuer on each such vest date. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 19:40 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | SaleCommon Stock | 300 | $30.01 | $9,003.00 |
DisclosureSEC source: 0001209191-21-053042 · doc4.xml · nonDerivative · entry 2 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on April 9, 2021. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 19:40 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | Exercise / conversionCommon Stock | 300 | $4.61 | $1,383.00 |
DisclosureSEC source: 0001209191-21-053042 · doc4.xml · nonDerivative · entry 1 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 19:00 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | GrantStock Option (Right to Buy) · Derivative | 63,000 | $0.00 Strike: $56.61 | $0.00 |
DisclosureSEC source: 0001209191-21-017310 · doc4.xml · derivative · entry 1 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Stock · 63,000 shares Expires 2031-03-01 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall become vested and exercisable on April 1, 2021 and 1/48th of the shares subject to the option shall become vested and exercisable each month thereafter, provided that the reporting person is a service provider to the issuer on each such vest date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.